Replies to post #14993 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

I agree but I think we are store coming years of excitement. ANIP's revenue and profit margins are due to increase at an accelerated pace.

ANIP currently has a profit margin of 6.56 % on 517.46 million (TTM). I figure it will closer to a profit margin of 22.33% on revenue over $950 million by 2028 increasing to a profit margin of 27% on revenue $1.13 billion by 2031. None of this includes royalties from CG Oncology or any revenue related to Libigel.

It has taken a while but the long awaited run looks imminent.

JMHO

[Just the facts maam]

Silvr, if the 505(b)(2) filing is for a liquid terazosin, it would be the first FDA approve liquid Alpha1 blocker, which could syphon sales from the other Alpha blockers in addition to terazosin. We should see a PPS pop when announced and a big pop if approved. According to the patent it look like it would benefit hospitals looking for rapid absorption and patients having difficulty swallowing. Ten percent of Terazosin prescriptions in 2021 would be approximately 173,000 prescriptions. However, if it attracts from other Alpha 1 blockers at a 10% rate (2021 stats), it would be approx. 3.5 million prescription. I imaging the price would be much more than the tablets or capsules now available as generics.

It makes it very interesting that Samy was selling shares knowing that this filing was in the works. Obviously he needed the money. Mostly likely to fund Esjay's expansion.

This could be huge.